Successfully reported this slideshow.
We use your LinkedIn profile and activity data to personalize ads and to show you more relevant ads. You can change your ad preferences anytime.

Contract Biomanufacturing Services Global Market - Forecast to 2025


Published on

Market Research Reports, Inc. has announced the addition of “Contract Biomanufacturing Services Global Market - Forecast to 2025” research report to their offering. See more at -

Published in: Healthcare
  • Be the first to comment

Contract Biomanufacturing Services Global Market - Forecast to 2025

  1. 1. Category : Healthcare All logos and Images mentioned on this slide belong to their respective owners.
  2. 2. Introduction to Report  Launch Date: August 17, 2017  Number of Pages: 206  Geography Coverage: Global  Available Format: PDF Price For Single User License: USD 3,600 Price For Site User License: USD 5,400 Price For Global User License: USD 7,200 Delivery Time: Within 24 Hours (During Working Days)
  3. 3. About the Report The contract biomanufacturing global market is expected to grow at double digit CAGR to reach $36.6 billion by 2025. Biomanufacturing is a widely used term to describe manufacture of biologic molecules for various stages of drug development right from pre-clinical stage to commercial supply. The biologic drug manufacturing is a complex process involving huge capital and sound technical expertise.
  4. 4. Key Highlights: Many large and small pharmaceutical companies are turning to outsourcing the drug manufacture process to reduce capital investments on capacities and focus more on their core competencies. Contract manufacturing organizations, particularly for R&D and clinical trials, are making product manufacture, more efficient and often less costly. This option is more viable for smaller and low-funded companies for their in-house candidate product manufacturing needs, whereby, the companies can avoid $50-$150 million facility costs for construction of fixed, dedicated stainless steel bioreactor-based bioprocessing systems and outsource their manufacturing requirements to CMOs which use single- use facilities which typically cost $25-$40 million for commercial manufacture.
  5. 5. Key Highlights: Continues.. ere is a continued growth of biopharmaceutical market which is expected to nearly double in next 10 years. This will be a result of continued new product approvals, expansion of indications for current products which include less-developed countries becoming more affluent and increased drug demand of the aging population in the U.S. and other major pharmaceutical markets. Aging populations are at a high risk of developing chronic diseases such as cancer and arthritis and these diseases are being precisely targeted using biopharmaceuticals. Many blockbuster drugs losing their exclusivity are also giving room for many biosimilar (and bio-betters) companies to enter into the world’s biopharmaceuticals market subsequently attracting many CROs, CDMOs, and CMOs to enter into the picture.
  6. 6. Key Highlights: Continues.. Now-a-days CMOs are gaining much prominence due to increased demand for the clinical and commercial supply of biologics. Such prominence is achieved mainly through capacity expansions or more easily through mergers and acquisitions. In September 2016, Asahi Glass, a Japanese manufacturer of glass, chemicals, and high-tech materials acquired a leading European bio-CMO, Biomeva Holding GmbH to expand their life science business and expand into newer geographies. Contract manufacturing services are mainly benefitting the small scale companies which lack the facilities for the biomanufacturing and also intend to not invest in fixed assets like steel bioreactors and bioprocessing facilities thus giving opportunity for the CMOs to gain market presence.
  7. 7. Key Highlights: Continues.. The global bio-manufacturing outsourcing market is driven by factors such as globalization of bio- manufacturing facilities, increased funding from private venture capitals and government organizations, increasing outsourcing budgets and emergence of latest technologies such as single-use bioreactors. Increased funding has been seen as a boon for Chinese CMOs for becoming a lucrative market for biomanufacturing outsourcing. An example of such funding includes Autek Bio who raised an impressive $100 million for building Asia’s largest CMO facility in south Beijing from private and government sources. There are restraints and threats as well which could potentially hamper the biomanufacturing outsourcing market.
  8. 8. Report Coverage: 1. Contract Biomanufacturing Global Market 2. Executive Summary 3. Contract Biomanufacturing Services 4. Company Profiles For more details regarding Report coverage see the last slide All logos and Images mentioned on this slide belong to their respective owners.
  9. 9. Company Coverage: (Partial List) 1. Abzena Plc 2. Albany Molecular Research, Inc 3. Asahi Glass Co. Ltd. 4. Boehringer Ingelheim 5. Catalent Inc 6. Charles River Laboratories 7. Fujifilm Diosynth Biotechnologies 8. Horizon Discovery Group, Plc 9. Innovent Biologics 10. Jhl Biotech Inc. 11. Lonza Group 12. Merck Kgaa 13. Patheon N.V. For more details regarding Report coverage see the last slide All logos and Images mentioned on this slide belong to their respective owners.
  10. 10. Custom Research:  Are you an industry professional, entrepreneur, venture capitalist, investors and organization, then let us know your specific research requirements. Our goal is to cater to your requirements be it for a custom market research project, syndicated research report on a specific market or industry sector, newsletter creation, case study development or anything else related to marketing research. For Any Customization Related query Visit IdeaCenter @ For regular industry updates subscribe to our newsletter at: newsletter
  11. 11. How To Buy This Report? Visit following URL to see Table of Content and purchase this publication: About Market Research Reports, Inc. Market Research Reports provides a customized set of reports from reputed Publishers, built on the intelligence available within organizations and leverages on our motto of “Intelligence Redefined”. Contact : Mr. Sudeep Chakravarty Email : Phone: +1-302-703-9904 (USA) +91-8762746600 (India)